Headlines about ABIOMED (NASDAQ:ABMD) have trended positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABIOMED earned a news impact score of 0.29 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.3467037258349 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s scoring:

A number of brokerages have recently commented on ABMD. BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research report on Sunday, October 29th. Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Jefferies Group LLC raised their target price on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, Piper Jaffray Companies lifted their price objective on shares of ABIOMED to $200.00 and gave the company an “overweight” rating in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $185.38.

Shares of ABIOMED (NASDAQ ABMD) traded down $1.29 during mid-day trading on Monday, reaching $198.45. 289,165 shares of the company traded hands, compared to its average volume of 336,629. The stock has a market capitalization of $8,831.70, a price-to-earnings ratio of 128.04, a price-to-earnings-growth ratio of 2.66 and a beta of 0.23. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. ABIOMED has a 12 month low of $103.53 and a 12 month high of $200.28.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.16. The company had revenue of $132.80 million for the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. ABIOMED’s revenue was up 28.9% compared to the same quarter last year. During the same period last year, the company posted $0.20 earnings per share. analysts anticipate that ABIOMED will post 2.38 EPS for the current fiscal year.

In other ABIOMED news, VP Andrew J. Greenfield sold 11,282 shares of ABIOMED stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $169.32, for a total value of $1,910,268.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Eric A. Md Rose sold 982 shares of ABIOMED stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $145.17, for a total transaction of $142,556.94. Following the completion of the transaction, the director now directly owns 13,634 shares in the company, valued at $1,979,247.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,628 shares of company stock worth $4,978,890. 7.00% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “ABIOMED (ABMD) Getting Favorable Media Coverage, Accern Reports” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/11/27/abiomed-abmd-getting-favorable-media-coverage-accern-reports.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.